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INTRODUCTION
Hepatocellular carcinoma (HCC) is a major health problem responsible for fifth most 
common neoplasm in the world, and third most common cause of cancer related deaths. i Age 
adjusted incidence is 5.5 – 14.9 per 100,000 population worldwide. Age adjusted incidence 
for HCC in developing countries are two to three fold higher than those in the developed 
countries.ii Almost 80% of liver cancers occur in developing countries like Asia and Africa.iii A 
rise  in  the  incidence  of  mortality  from  HCC  has  been  observed  in  different  countries. iv 
Approximately 77% of deaths from HCC occur in developing countries. 
The prognosis of HCC is dismal with 5-year survival being 1–4%.3 Global distribution of 
HCC  is  very  variable.  Most  Western  countries  have  a  low  HCC  incidence  (<5  cases/ 
y/100,000), but most Asian countries have an intermediate (5–15 cases/y/1,000,000) or high 
(>15 cases/y/100,000) incidence of HCC. v Low incidence of <5 cases/y/100,000 of population 
has  been  reported  from  India.vi This  low  incidence  is  in  contrast  with  the  widespread 
contamination of foods with mycotoxins and the moderately high prevalence of hepatitis B 
virus  (HBV) and hepatitis  C virus (HCV) related chronic  liver  disease in  India,  which are 
considered as the most important risk factors for the development of HCC worldwide.
In India, the mean incidence of HCC in four population-based registries is 2.77% for 
males and 1.38% for females. The prevalence of HCC in India varies from 0.2% to 1.6%.vii 
Hepatitis B virus infection is the most common etiologic factor in high incidence areas, while 
hepatitis  C infection  is  more  prevalent  in  the  low incidence  areas.  viii ix Unlike  other  low 
incidence zone, in India HBV is the main etiological factor associated with HCC. x xi xii  In the 
west, majority of HCC are diagnosed incidentally during routine evaluation. However, in India, 
most  of  the patients  in clinical  practice present  at  an advanced stage ruling out  curative 
treatment in most cases.
Despite India being a low incidence zone for HCC, the estimated HCC cases in 2001 
was 12 750.7  However, there is paucity of published literature on profile of HCC patients in 
India,  making formulation of  a proper  health  care strategy difficult.  Most  of  the published 
literatures were retrospective studies and moreover limited number of studies available for 
South Indian population. Hence we have undertaken this study to analyze the characteristics 
of HCC, especially with regard to their clinical, etiological, radiological and cytohistological 
profile.
AIMS & OBJECTIVE OF THE STUDY
The study was conducted with the objective of 
a) To study the clinical, etiological, radiological and cytohistological profile in patients with 
Hepatocellular carcinoma
b) To identify the association between serum alpha fetoprotein with stage of the disease. 
REVIEW OF LITERATURE
Hepatocellular carcinoma (HCC) represents more than 5% of all cancers in the world, 
and  the  estimated  number  of  cancer-related  deaths  exceeds  500,000  per  year. xiii Most 
patients  who  have  HCC are  diagnosed at  advanced stages leading  to  an  overall  1-year 
survival of 25%.xiv With the significant increase in the number of patients who have HCC, early 
detection and treatment of this tumor are vital to improve outcomes.xv 
Epidemiology
Worldwide Distribution
Liver cancer burden is not distributed evenly throughout the world.  According to the 
age adjusted HCC incidence per 100 000 population per annum, different geographic regions 
can be divided into three incidence zones: low (<5), intermediate (between 5 and 15), high 
(>15).5 More than 80% of HCC cases occur in either sub-Saharan Africa or in Eastern Asia. 
China alone accounts for more than 50% of the world’s cases (men, 35.2/100,000; women, 
13.3/100,000). North and South America, and Northern Europe found to have low incidence 
(<5.0/100,000) of liver cancer among most populations. United Kingdom (male, 2.2/100,000; 
female, 1.1/100,000), and Australia (male, 3.6/100,000; female, 1.0/100,000) also noted low 
tumor burden.  xvi Neonatal vaccinations against hepatitis B virus (HBV) and shift the staple 
diet from corn to rice (limit the exposure to aflatoxin B1 lowered the incidence of HCC in Asian 
countries.xvii xviii
Race/Ethnicity
HCC  incidence  rates  vary  greatly  among  different  populations  living  in  the  same 
region. In United States, HCC rates are 2 times higher in Asians than in African Americans, 
whose rates are 2 times higher than those in whites. The reason for this ethnic variability 
likely includes differences in the prevalence and acquisition time of major risk factors for liver 
disease and HCC.16
Sex
In almost all populations, males have higher liver cancer rates than females, with male: 
female ratios usually averaging between 2:1 and 4:1. At present, the largest discrepancies in 
rates (>4:1) are found in medium-risk European populations.xix The reasons for higher rates of 
liver cancer in males may relate to sex-specific differences in exposure to risk factors. Men 
are more likely to be infected with HBV and HCV, consume alcohol, smoke cigarettes, and 
have increased iron stores. Several  studies conducted in Taiwanxx xxi  reported a positive 
association between increased circulating testosterone levels and HCC in HBV-infected men.
Age
The  global  age  distribution  of  HCC varies  by  region,  incidence  rate,  sex,  and  by 
etiology.16 In all areas, female rates peak in the age group 5 years older than the peak age 
group  for  males.  In  low-risk  populations  (United  States,  Canada,  and  United  Kingdom), 
commonly occurs among persons aged 75 and older. A similar pattern is seen among most 
high-risk Asian populations (Hong Kong and Shanghai). In contrast, male rates in high-risk 
African  populations  tend  to  peak  between  ages  60  and  65,  whereas  female  rates  peak 
between 65 and 70. These variable age specific patterns likely are related to differences in 
the dominant hepatitis virus in the population, the age at viral infection, and the existence of 
other  risk  factors.19Although  most  HCV  infections  acquired  in  adulthood,  but  most  HBV 
carriers became infected at very young ages.
Distribution of Risk Factors
In low-rate HCC areas, the increasing number of persons living with cirrhosis is the 
likely explanation for the increasing incidence of HCC. Combination of factors including an 
increasing incidence of cirrhosis caused by HCV, HBV infection, as well as an improvement in 
survival among cirrhosis patients.19
In most high-risk areas, the dominant risk factor is chronic HBV infection. In Asia, HBV 
infection  largely  is  acquired  by  maternal-child  transmission,  whereas  sibling-to-sibling 
transmission at young ages is more common in Africa. Consumption of AFB1 -contaminated 
food is the other major HCC risk factor in most high-rate areas. 
By contrast, in Japan, Egypt and in Southern Europe, HCV is the main cause of HCC 
which  occurs  in  older  patients,  nearly  all  of  them with  advanced  fibrosis  or  cirrhosis.  In 
Northern and Central European countries, HCV infection and alcohol are the main causes of 
cirrhosis. In France, ethanol is still the leading cause of cirrhosis and was responsible for 60% 
of all HCC cases.xxii
HCC in Asia
In China and Taiwan, almost one-fifth of the populations are carriers of HBV, and the 
majority of persons with HCC are HBsAg-positive. xxiii Although HCV infection is the main risk 
factor  in  HbsAg negative  HCC,  HCV prevalence is  low,  with  only 0.9% of  healthy blood 
donors positive for anti-HCV.xxiv In contrast to the rest of Asia, cases of HCC in Japan are 
mainly  related  to  HCV infection,  and its  incidence is  rising  but  on  a  larger  scale.xxv The 
reasons underlying this difference are likely related to the wide transmission of HCV to young 
people in Japan from contaminated blood and needles after the Second World War. It also 
seems that in Japanese patients with chronic viral hepatitis, the progression to HCC occurs at 
an accelerated rate in HCV infection compared with HBV infection.
HCC in India
Most Asian countries are in intermediate or high incidence zones of HCC. In India, the 
mean incidence of HCC in four population-based registries is 2.77% for males and 1.38% for 
females. HCC accounted for 1.9% of the 24,975 cases of cancers recorded at 6 registries put 
together; the proportion ranging from 1.1% (94/8763) in Delhi to 5.3% (10/187) in Barshi rural 
registry. xxvi, xxvii The prevalence of HCC in India varies from 0.2% to 1.6%.7, 27 Unlike other low 
incidence  zone,  in  India  HBV is  the  main  etiological  factor  associated  with  HCC.10,  11,  12 
However, in India, most of the patients in clinical practice present at an advanced stage ruling 
out  curative  treatment  in  most  cases.  A  prospective  study by Paul  et  alxxviii revealed  the 
estimated incidence of HCC among cirrhotic patients was 1.6% per year.
Risk Factors and Pathogenesis of HCC
Hepatocellular  carcinoma is  multifactorial  in  etiology and complex in  pathogenesis. 
Several risk factors have been described in various studies. 
Risk Factors for Hepatocellular Carcinoma
Major Risk Factors 
 Chronic hepatitis B virus infection 
 Chronic hepatitis C virus infection 
 Cirrhosis 
 Dietary exposure to aflatoxin B1 
Minor Risk Factors 
 Oral contraceptive steroids 
 Cigarette smoking 
 Dietary iron overload in persons of black African ancestry 
 Hereditary hemochromatosis 
 Wilson disease 
 α1-Antitrypsin deficiency 
 Type 1 hereditary tyrosinemia 
 Type 1 and type 2 glycogen storage disease 
 Membranous obstruction of the inferior vena cava
Hepatitis B Virus (HBV)
Globally,  HBV is  the  most  common cause  of  HCC,  with  an  estimated  300  million 
persons with chronic infection worldwide. Case-control studies have shown that chronic HBV 
carriers have a 5- to 15-fold increased risk of HCC compared with the general population. The 
great  majority,  between  70%  and  90%,  of  HBV-related  HCCs  develop  in  patients  with 
cirrhosis. However, HCC may occur in HBV infected individual in the absence of cirrhosis.
The risk of HCC in patients with chronic HBV infection depends on age, carrier status, 
inflammation, presence of cirrhosis and the family history of HCC.xxix Prospective studies have 
shown that  the  annual  incidence  rate  is  between  2.2% and  4.3% for  patients  with  HBV 
cirrhosis, between 0.1% and 1% in patients with chronic hepatitis, and between 0.02% and 
0.2% in inactive carriers.xxx
The increased HBV related  HCC risk  associated  where  HBV is  endemic.  In  these 
areas, vertical transmission is the usual mode of acquiring infection seen up to 90% of chronic 
infected persons. This pattern is different in areas with low HCC incidence rates where HBV is 
acquired in adulthood through sexual and parenteral  routes (horizontal  transmission); with 
only 10% become chronic HBV carriers. The annual HCC incidence in chronic HBV carriers in 
Asia ranges between 0 .4% and 0.6%. 
The HBsAg positivity in Indian HCC patients varies from 36% to 74%.  10,  11,  xxxi India 
despite being in an intermediate endemic zone for HBV has low incidence of HCC unlike 
other Asian countries. The relative risk of developing HCC in Indian patients with chronic 
HbsAg infection was estimated to be 7.8 from various studies.xxxii The prevalence of Hepatitis 
B and C infection in HCC patients is as follows in table 1. 
Groups at high risk for HCC among Hepatitis B carriers are Asian males > 40 years 
old, Asian females > 50 years old, cirrhosis, family history of HCC and patients who do not 
have cirrhosis: depends on viral genotype, viral replication 
Table 1 Prevalence of hepatitis B and C in HCC
Place No of patients
HbsAg + ve
(%)
Anti HCV + ve
(%)
Sarin et al 2001, Delhi12 74 71 4
Joshi  et  al  2003, 
Hyderabadxxxiii
40 47.5 20
Saini  et  al  2006, 
Chandigarhxxxiv
47 54 27
Kumar et al 2008, Delhixxxv 246 73 15
and inflammatory activity.29 HCC risk also is increased in patients with higher levels of HBV 
replication (HBeAg positivity and high HBV-DNA levels). 
Spontaneous  or  treatment-induced  development  of  antibodies  against  hepatitis  B 
surface antigen and HBeAg, found to have improved clinical outcomes against HCC. A meta-
analysis of 12 studies, patients with chronic HBV infections treated with or without interferon 
therapy followed  up  for  5  years  found  a  lower  HCC incidence in  treated  than  untreated 
patients.xxxvi However, this difference was not statistically significant. Occult HBV infection has 
been associated with increased risk of HCC, but this fact is not proven yet. The risk of HCC is 
substantially lower in persons who are immune to HBV. Beasley found that the incidence of 
HCC was significantly lower in immune persons compared with carriers (5 vs 495 per 100,000 
per year). xxxvii 
Hepatitis B vaccination is widely recognized as the most effective measure to prevent 
HBV infection and HBV-associated complications, including HCC. The first evidence came 
from Taiwanese studyxxxviii showed that  HCC is  preventable via  effective  vaccination.  The 
average incidence of  HCC declined from 0.7 (1982 to  1986)  to  0.36 (1990 to  1994)  per 
100,000 children. And there was a similar decline in the mortality associated with HCC.
Integration of HBV DNA into host’s genome may activate cellular proto-oncogenes or 
suppress  growth-regulating  genes  in  cis.  HBV-related  tumors  have  a  distinct  pattern  of 
genetic mutation with greater chromosome instability than HCC with higher prevalence of loss 
of heterozygosity has been correlated with tumor aggressiveness. The HBV X gene encodes 
a viral protein that plays a central role in HBV infection and in hepatocarcinogenesis. The HBx 
protein  is  a  transcriptional  factor  that  can  alter  the  expression  of  many  cellular  genes, 
including oncogenes such as c-myc and        c-myb, as well as tumor suppressor genes such 
as APC, p53, p2.xxxix The X protein has the ability to block p53 mediated apoptosis in vivo, 
which contributes to the development of  preneoplastic  and neoplastic hepatocytes.  It  has 
been also demonstrated that core promoter mutations, T1653 mutations, HBV DNA levels 
≥4log10 copies/mL and presence of cirrhosis were independent factors for the development 
of HCC.xl 
HBV-related HCC is predominant in male, with a male to female ratio of 5–7:1. This is 
attributed to the elevated androgen level and the enhanced androgen receptor (AR)-mediated 
activity in the host. HBx is a noncellular positive coregulator for androgen receptors makes 
males vulnerable to HBV infection and the subsequent development of cancer.xli HBx protein 
may  play  a  significant  role  in  inducing  the  expression  of  angiopoietin-2;  contribute  to 
pathological angiogenesis and hepatocellular carcinoma progression.xlii
Chronic Hepatitis C
Chronic HCV infection is the emerging cause of HCC in industrialized countries with 
the reported prevalence of more than 80% in Japan, Italy and Spain.  There is geographic 
variability in the prevalence of markers of HCV infection in patients who have HCC; it has 
ranged from 27% in the United States, from 27%s to 75% in Western Europe and up to 80% 
to 90% in Japan.xliii The risk of HCC in patients with chronic hepatitis C is present mainly in 
patients with established cirrhosis, in whom the incidence of HCC is between 2 and 8% per 
year.xliv A  large  community-based  prospective  study  from  Taiwan  that  included  12,008 
patients observed a 20-fold increased risk for developing HCC in anti–HCV-positive patients 
when compared with anti–HCV-negative subjects.xlv The estimated risk of developing HCC 
depicted in Figure 1 based on study by Hassan et al. xlvi In Chronic HCV-infected patients, 
host  and  environment  factors  appear  to  play  more  important  role  than  viral  factors  in 
determining progression to cirrhosis. These factors include older age, older age at the time of 
acquisition of infection, male sex, heavy alcohol intake (>50 g/day), diabetes, obesity, and co-
infection with human immunodeficiency virus or HBV.14 HCV viral factors such as genotype, 
load, or quasispecies are not important in determining the risk of progression to cirrhosis or 
HCC. Successful antiviral therapy in patients with HCV related cirrhosis may decrease HCC 
risk moderately among patients treated with interferon.xlvii xlviii
Figure 1 Proportion of 
patients with HCC 
related to HCV viral  
infection.
Unlike HBV, HCV 
is  an  RNA  virus  that 
does not integrate into the host genome and host-viral protein. At least four of the HCV gene 
products HCV core, NS3, NS4B and NS5A, alter several potentially oncogenic pathways. It 
has been demonstrated that HCV Core could contribute to viral persistence by regulating anti-
apoptosis factors that could prevents apoptosis and enhance the survival of HCV infected 
host cells. The HCV core protein regulates transcription of different cellular genes, including 
the  proto-oncogene  c-myc,  suggesting  its  involvement  in  the  deregulation  of  normal  cell 
growth. HCV core protein would be involved in hepatocarcinogenesis through two different 
molecular pathways; 1) the core protein would act on the function of mitochondria, leading to 
oxidative stress, which yields genetic aberrations in cell growth-related genesxlix 2) Modulation 
of  gene  expressions  and  intracellular  signal  transductions.  The  combination  of  these 
alterations would provoke the development of HCC in HCV infection.49
HCV nonstructural proteins NS3 and NS5A were shown to possess direct oncogenic 
potential.  Positive correlation identified between COX-2 and iNOS expression with hepatic 
angiogenesis in HCV-positive HCCs, suggesting role in tumor angiogenesis. Two phenotypes 
such  as  angiogenic  and  MDR  (Multi-Drug  Resistance)  have  been  described.   Both 
phenotypes  are  correlated  to  aggressiveness  of  cancer  and  prognosis  of  patients. l MDR 
phenotype in cancer cells express a glycoprotein (P-gp) that binds hydrophobic molecules, 
including chemotherapic agents, and exports them out of the cell by ATP hydrolysis. li This 
favors tumor cell survival and proliferation. Induction of MDR phenotype is associated with an 
up-regulation of the COX-2 and iNOS in human HCC cell lines. COX-2 is associated with 
different cellular functions and is over expressed in several human tumors. PGs and NO play 
an important role in tumor growth, angiogenesis. Evidence suggested that the MDR and the 
angiogenic phenotypes are linked to each other in human liver cancer cells.lii 
Co-infection with HIV:
Patients co-infected with HIV and either  hepatitis  B or  hepatitis  C may have more 
rapidly progressive liver disease and when they reach cirrhosis they are also at increased risk 
of HCC. The MORTAVIC study indicated that HCC was responsible for 25% of all liver deaths 
in the post-HAART era.liii 
Treated chronic HBV and HCV infections
There  is  no  convincing  evidence  that  interferon  treatment  of  chronic  hepatitis  B 
reduces the incidence of HCC. Studies which shown in decrease reduction in the incidence of 
HCC  with  lamivudine  or  interferon  therapy,  the  event  rate  was  low.  A  meta-analysis 
conducted in patients with chronic HCV infection concluded that the benefit with interferon 
treatment was mainly seen in those who achieved sustained virological response, however 
the effect was small. The steps required to initiate the carcinogenic pathway probably occur 
many years before the disease becomes inactive, and so the threat of HCC remains even if 
fibrosis decreases. Regressed fibrosis is not a rationale to withhold surveillance.29
Cirrhosis
Most often HCC occurs within an established background of chronic liver disease and 
cirrhosis (70%–90% of all detected HCC cases). Major causes of cirrhosis in patients with 
HCC  include  hepatitis  B,  hepatitis  C,  alcoholic  liver  disease,  and  possibly  nonalcoholic 
steatohepatitis.  Less  common  causes  include  hereditary  hemochromatosis,  alpha-1 
antitrypsin deficiency, autoimmune hepatitis, and some porphyrias.
Cirrhosis  is  macronodular  and is  often attributed to  chronic  HBV infection in 
Chinese and African populations, whereas in other populations, cirrhosis is commonly mixed 
macronodular  and  micronodular.  Micronodular  cirrhosis  may  results  from  chronic  HCV 
infection,  alcohol  abuse, or both.  Cirrhosis contributes to  hepatocarcinogenesis mainly by 
acting as a potent tumor promoter. Incidence of HCC in compensated cirrhosis enumerated in 
table 2. Male sex, age, and duration of cirrhosis are the major risk factors for hepatocellular 
carcinoma in cirrhotic patients. 
Table 2 Incidence of HCC in Patients with Compensated Cirrhosis
Fattovich 
et al,liv 
Italy
Hu and 
Tong,lv
United 
States
Serfaty 
et al.lvi
France
Paul et 
al28
India
Number of patients 384 112 103 301
Follow-up period, y 5.0 4.5 3.3 4.0
HCC, % per year 1.4 2.3 3.3 1.6
Aflatoxin
AFB1 is a mycotoxin produced by the Aspergillus fungus. This fungus grows readily on 
foodstuffs  such  as  rice,  corn  and  peanuts  stored  in  warm,  damp  conditions.  AFB1  is  a 
powerful  hepatocarcinogen,  leading  the  International  Agency  for  Research  on  Cancer  to 
classify it as carcinogen. After ingestion AFB1 is metabolized to an active intermediate, AFB1 
-exo-8, 9-epoxide, which can bind to DNA and cause mutation in the p53 tumor-suppressor 
gene.  This  mutation  observed  in  30%–60% of  HCC tumors  in  aflatoxin-endemic  areas.lvii 
Strong evidence of AFB1 is a risk factor for HCC based on epidemiologic studies. 
Short-term prospective studies have analyzed the interaction between AFB1 exposure 
and chronic  HBV infection.  It  has  been found that  aflatoxin  and HBV infection  exposure 
increases 4-fold and 7-fold risk of HCC respectively. However, individuals exposed to both 
showed 60-fold increased risk of HCC.lviii In most areas where AFB1 exposure is a problem, 
chronic HBV infection also is highly prevalent. 
A study lix from Indian subcontinent reported the prevalence of aflatoxin B1 (AFB1) in 
31 liver biopsies and 7 liver-resection specimens from histopathologically proven HCC. 58.1% 
of HCC cases showed AFB1 in liver biopsies. Positive for AFB1 in liver biopsy noted in 46.1% 
of HBsAg-positive patients,  which proves that aflatoxin have a significant association with 
HCC.
Minor risk factors
Oral Contraceptives: Studies showed a significant 2- to 20-fold increase in HCC risk 
with longer durations (>5 y)  of oral  contraceptive (OC) use. This has been reported from 
countries with low incidence of HCC. Nuclear estrogen receptors exist in hepatocytes and 
estrogens  are  thought  to  cause  liver  neoplasia  by  increasing  proliferation  rates,  thereby 
increasing rates of spontaneous mutations. OC use also has been linked to malignant liver 
tumors  such  as  mixed  hepatocellular  and  ductal  carcinoma,  cholangiocarcinoma,  and 
hepatoblastoma.50
Hemochromatosis:  A population-based study conducted in  Sweden using multiple 
national  data sources indicated a 1.7-fold increase in the incidence of HCC among 1800 
individuals with hereditary hemochromatosis.  Malignant transformation common observed in 
the presence of cirrhosis, but this has been reported in patients without cirrhosis. It is possible 
that  excessive  free  iron  in  tissue may be carcinogenic  by generating  mutagenic  reactive 
oxygen species. lx
Conflicting  evidence  observed  between  cigarette  smoking  and  the  occurrence  of 
hepatocellular carcinoma based on epidemiologic studies. But most of the evidence suggests 
that  smoking is  a  minor  risk factor.  Heavy smokers have a 50% higher  risk than that  of 
nonsmokers. The cytochrome P450 enzyme system responsible for the metabolic activation 
of a number of chemical carcinogens is highly inducible by smoking.lxi           
      Hepatocellular  carcinoma  develops  in  nearly  40%  of  patients  with  membranous 
obstruction  of  the  inferior  vena  cava,  reported  in  Asian  and  African  countries.  Repeated 
hepatocyte  necrosis  followed  by  regeneration  resulting  from  the  severe  and  unremitting 
hepatic venous congestion makes the cells susceptible to environmental mutagens, as well 
as to spontaneous mutations.lxii 
 Clinical features
In advanced disease, patients with hepatocellular carcinoma often present with typical 
symptoms and signs. Clinical recognition often is difficult in early stages. The clinical picture is 
very variable
Asymptomatic Presentation
Since  the  easy  availability  of  imaging  techniques,  increasing  numbers  of  cirrhotic 
patients are being diagnosed with HCC at asymptomatic stage. These tumors tend to be 
smaller with current imaging methods, tumors as small as 0.5 cm can be detected with newer 
techniques.  Therefore these tumors are more amenable to potentially curative therapies such 
as resection, transplantation, and tumor ablation. The frequency of asymptomatic diagnosis is 
dependent on the intensity of the screening on high risk patients. In a series of 461 Italian 
patients, asymptomatic HCC was detected in 23%. lxiii
Hepatic Decompensation
Another  common  scenario  for  the  presentation  of  HCC  is  sudden  hepatic 
decompensation in a patient known to have cirrhosis. New-onset ascites, recurrent variceal 
hemorrhage,  or  progressive encephalopathy should always  raise  suspicion  for  HCC.  The 
ascites may be difficult to control with standard diuretic therapy and often is bloodstained.
Gastrointestinal Hemorrhage
Approximately 10% of patients have gastrointestinal bleeding at presentation. In 40% 
of these patients, the bleeding is the result of esophageal varices resulting from portal vein 
invasion and elevated portal pressure. Peptic ulcer disease and other benign causes account 
for the remaining 60% of cases involving bleeding. Rarely, the tumor directly may invade the 
gastrointestinal tract and causes bleeding.
The “Classic Triad”
In clinical practice, HCC often present with the triad of right upper quadrant abdominal 
pain, weight loss, and hepatomegaly. Patients with these symptoms at presentation usually 
have a tumor larger than 6 cm. The pain frequently is described as a dull continuous ache 
that intensifies late in the course of the illness due to involvement of Glisson’s capsule. The 
pain  may be  referred  to  the  shoulder.  Firm,  often  massive,  nodular  hepatomegaly is  an 
invariable feature of symptomatic HCC. An arterial vascular bruit due to increased vascularity 
may be a useful diagnostic pointer. It is observed in 25% of cases, occurs in systole, rough in 
character, and is not affected by changing the position. Although not pathognomonic, it rarely 
occurs with hepatic metastases.lxiv 
Tumor Rupture: “Hemoperitoneum”
Spontaneous rupture is a rare and catastrophic complication of HCC that may occur if 
a large vascular tumor on the periphery of the liver. It may occur spontaneously or with minor 
blunt abdominal trauma. The clinical presentation is that of severe abdominal pain, vascular 
collapse, and signs of peritoneal irritation. Although hemoperitoneum is a frequent event late 
in the course of the disease, it is a presenting feature in less than 5% of cases. The diagnosis 
is  established  by  paracentesis,  which  reveals  bloodstained  fluid.  Angiography  and 
embolization  of  the  bleeding  vessel  can  be  an  effective  method  for  managing  this  life-
threatening complication. 
Extrahepatic Endocrine and Paraneoplastic Syndromes
These systemic  sequelae  result  from synthesis  and secretion  of  biologically active 
substances  by the  tumor.  Advances have  been  made in  understanding  the  mechanisms 
underlying  some  of  these  paraneoplastic  phenomena.  Less  than  5%  of  patients  results 
hypoglycemia. Type A hypoglycemia is a milder form of glycopenia that occurs in the terminal 
stages of hepatocellular carcinoma due to increased demands for glucose by a large rapidly 
growing tumor. Type B hypoglycemia is believed to result from the defective processing by 
malignant  hepatocytes  of  the  precursor  to  insulin-like  growth  factor  II  (pro-IGF-II). 
Polycythemia (<10% of patient) is caused by synthesis of erythropoietin by the tumor. 
Patients with sclerosing type of HCC may present with hypercalcemia in the absence 
of  osteolytic  metastases.  The probable cause is secretion of  parathyroid hormone-related 
protein by the tumor. Arterial hypertension complicating HCC is the consequence of ectopic 
synthesis of angiotensinogen by malignant hepatocytes. Feminization results from the tumor’s 
conversion  of  circulating  dehydroepiandrosterone  to  estrone.  Hypercholesterolemia  is  the 
result  of  de  novo  synthesis  of  cholesterol  by the  tumor.  Watery  diarrhea  is  occasionally 
severe and intractable,  probably is related to secretion of peptides that promote intestinal 
secretion  such  as  vasoactive  intestinal  peptide,  gastrin,  and  prostaglandins.  Cutaneous 
manifestations  are  not  specific  for  the  diagnosis  of  HCC.  It  includes  dermatomyositis, 
pemphigus foliaceus, sign of Leser-Trelat, pityriasis rotunda, and porphyria cutanea tarda.
Paraneoplastic Syndromes Associated With HCClxv
• Hypoglycemia
• Polycythemia (erythrocytosis)
• Hypercalcemia
• Sexual changes: isosexual 
precocity, gynecomastia, 
feminization
• Systemic arterial hypertension
• Watery diarrhea syndrome
• Carcinoid syndrome
• Osteoporosis
• Hypertrophic osteoarthropathy
• Thyrotoxicosis
• Hypercholesterolemia
• Thrombophlebitis migrans
• Polymyositis
• Neuropathy
• Cutaneous manifestations: pityriasis 
rotunda, Leser-Trelat sign, 
dermatomyositis,
• Pemphigus foliaceus, porphyria 
cutanea tarda
Other Rare Manifestations
Fever  of  unknown  origin  may  be  a  manifestation  of  HCC.  Massive  tense  ascites 
resulting from hepatic vein spread (Budd–Chiari syndrome) and obstructive jaundice resulting 
from bile  duct  compression  are  two  complications  of  locally  advanced tumor.  Other  rare 
presentations include bone pain (skeletal),  sudden paraplegia  (vertebral  destruction),  and 
cough or dyspnea (multiple pulmonary metastases).
Diagnostic Methods 
A diagnostic approach to HCC has been developed based on the literature and expert 
consensus and incorporates serology, cytohistology, and radiologic characteristics. Diagnosis 
of HCC can be confidently established by (1) a focal hepatic mass >2 cm is identified on one 
imaging technique wherein characteristic contrast enhancement features on the arterial phase 
with venous washout on an MRI or CT can be demonstrated; (2) a focal hepatic mass with 
atypical imaging findings (no arterial enhancement with washout), or a focal hepatic mass 
detected in a noncirrhotic liver, should undergo a biopsy.  lxvi  Diagnostic criteria formulated 
based on conclusion of the Barcelona-2000 EASL conferencelxvii
On the other hand, the recommended diagnostic approach for tumors >2 cm or tumors 
that do not meet above criteria is such that (1), when nodules within 1–2 cm on screening of a 
cirrhotic liver are typical of HCC (hypervascular with washout) on 2 imaging modalities, the 
lesion should  be treated  as HCC. In  an  atypical  lesion  where  the vascular  profile  is  not 
consistent  among  techniques,  a  biopsy  of  the  lesion  should  be  considered.  (2)  Nodules 
smaller than 1 cm should be followed with US at 3- to 6-month intervals.
Serum Markers 
α-Fetoprotein 
A large number of candidate markers have been advocated during the last 40 years, 
but  none  is  more  helpful  than  the  first  one  described  α-fetoprotein  (AFP).  AFP  is  a 
glycoprotein  that  normally  is  produced  during  gestation  by  the  fetal  liver  and  yolk  sac. 
Normally, it is present in high concentration in the fetal serum. AFP is elevated in approx 60–
70% of patients with HCC.  lxviii The normal range of this serum marker is 0–10 ng/mL, and 
levels higher than 400 ng/mL are diagnostic of HCC.67 False-positive results may be caused 
by acute and chronic benign hepatic diseases with a high necroinflammatory activity, germ 
cell tumors, or pregnancy. The sensitivity, specificity, and positive predictive value of AFP in 
three well-performed screening studies for HCC ranged from 39 to 64%, 76 to 91%, and 9 to 
32%, respectively.lxix  AFP production is age-related. Younger patients are more likely to have 
raised levels and to attain very high concentrations. There is no obvious correlation between 
serum AFP concentrations and any clinical or biochemical indices or the survival time after 
diagnosis. Because of both false-positive and false-negative results, serum AFP falls short of 
being an ideal tumor marker. Thus, a number of alternative substances have been suggested, 
although none have proved to be more useful than AFP. 
Several attempts have been made to improve the HCC specificity of AFP by measuring 
particular glycoforms of the protein. These isoforms have differential affinities for lectins such 
as Lens culinaris agglutinin and concanavalin A. Lens culinaris-reactive AFP, also known as 
AFP-L3, may be superior to total AFP as a marker of HCC. Other glycoforms, such as mono- 
and disialylated AFP, may also have increased sensitivity in HCC detection. However, data 
supporting their superiority over conventional AFP measurements are lacking.
Fucosylated AFP
AFP  is  heterogeneous  in  structure  with  differences  in  its  asparagine-linked 
oligosaccharide  side  chain.  The  resultant  differential  reactivity  with  lectins  is  used  in 
diagnosis.  Reactivity with lens culinaris agglutinin A is helpful  in distinguishing HCC from 
benign hepatic diseases and also to differentiate between HCC and other AFP-producing 
tumors.  The test  results  are  positive  in  approximately  35% of  patients  with  HCC tumors 
smaller than 2 cm, and this isoform of AFP may be present in serum up to 9 months before 
the detection of HCC by other methods. 
Des-γ-carboxy Prothrombin
Malignant hepatocytes seem to lack the ability to carboxylate glutamic acid to form γ-
carboxyglutamic acid.  The resulting abnormal  prothrombin has been referred to as des-γ-
carboxyprothrombin  (DCP).  Because  this  is  the  same  prothrombin  formed  by  vitamin  K 
absence or antagonism, DCP is also known as PIVKA-II. Although DCP has demonstrated a 
greater specificity than AFP, it still lacks sensitivity, especially for HCC tumors less than 3 cm 
in diameter, with sensitivity ranging from 19 to 48%. Compared with AFP, DCP levels had 
higher  sensitivity  and  specificity  in  differentiating  HCC  from  nonmalignant  chronic  liver 
disease. One prospective study screening cirrhotic patients for HCC, using cutoff values of 40 
ng/mL for AFP and 80 mAU/mL for DCP, showed 65% sensitivity and 85% specificity when 
both markers were combined.lxx 
α-L-Fucosidase
Alpha-L-fucosidase is a expressed lysosomal enzyme whose activity is detectable in 
the sera of healthy subjects. It might be useful as a complementary assay in conjunction with 
AFP.  The disease specificity  of  the a-L-fucosidase assay is  limited  since  non-cancerous, 
extrahepatic diseases such as diabetes, pancreatitis, and hypothyroidism are associated with 
elevated  serum  activities.  No  quantitative  serum  assays  are  currently  available,  and  the 
diagnostic potential of this marker remains unclear. Sensitivity and specificity of various tumor 
markers are given in table 3.
Table 3 Sensitivity and specificity of various tumor markers
Marker Sensitivity (%) Specificity (%)
Alpha-fetoprotein High-incidence  populations: 
80-90
Low-incidence  populations: 
50-70
90
Des-γ-
carboxyprothrombin
58-91 84
α-L-Fucosidase 75 70-90
Glypican-3
Glypican-3  (GPC-3)  is  a  cell-surface  glycoprotein  that  is  absent  in  hepatocytes  of 
healthy subjects and patients with hepatitis, but highly expressed in hepatocellular cancer 
cells.  GPC-3 is normally involved in the regulation of cell  proliferation and survival  during 
embryonal development and functions as a tumor suppressor. It is detectable in the serum in 
at least 50% of patients with HCC. Although still  experimental,  it  is of  interest because it 
seems to be expressed preferentially in small HCC tumors compared with larger HCC tumors.
Other Markers
Other markers of HCC that have been studied include tumor-associated isoenzymes of 
γ-glutamyl transpeptidase, urinary TGF-β-1, serum levels of circulating intercellular adhesion 
molecule  (ICAM)  -1,  Insulin-like  growth  factor-II  (IGF-II),  Insulin-like  growth  factor-binding 
protein-2  (IGFBP-2),  Human  cervical  cancer  oncogene  (HCCR),  Golgi  protein  73, 
Hepatocytes growth factor (HGF), KL-6, serum proteomics and HCC-specific auto-antibodies. 
None of these diagnostic tests have demonstrated superior accuracy compared with serum 
AFP. Two tumor markers, abnormal vitamin B12-binding protein and neurotensin have been 
linked specifically to the fibrolamellar variant of HCC. 
Diagnostic Imaging
Once a screening test is abnormal or there is a clinical suspicion that a patient may 
have HCC, imaging is very important for the diagnosis and staging of this tumor. 
Ultrasonography 
Ultrasonography often is  used as a screening method for  high-risk patients  and is 
repeated at frequent intervals. A small HCC may be hypoechoic, hyperechoic, or isoechoic on 
sonography. The ultrasonographic appearance is influenced by the presence of fat, calcium, 
and  necrosis.  Advantages  of  ultrasonography  include  safety,  availability,  and  cost 
effectiveness,  though  it  is  operator  dependent.  Approximately  two  thirds  of  symptomatic 
hepatocellular  carcinomas  are  uniformly  hyperechoic,  whereas  the  remainder  is  partly 
hyperechoic and partly hypoechoic.lxxi Ultrasonography with Doppler technology is useful for 
assessing the patency of the inferior vena cava, portal vein and its larger branches, hepatic 
veins, and biliary tree.71
CT scan and MRI
The most reliable diagnostic tests are triple-phase helical CT and triple-phase dynamic 
contrast enhanced magnetic resonance imaging (MRI)lxxii whereas hepatic angiography has 
fallen out of favor in most practice settings. HCC derives its blood supply predominantly from 
the hepatic artery, whereas the remainder of the nontumorous liver receives both arterial and 
portal  blood.  The  hallmark  of  HCC  during  CT  scan  or  MRI  is  the  presence  of  arterial 
enhancement  followed  by  delayed  hypointensity  of  the  tumor  in  the  portal  venous  and 
delayed phases (washout).lxxiii The presence of arterial enhancement followed by washout has 
a sensitivity and specificity of 90% and 95%, respectively.  However, 71% of patients with 
HCC will have arterial enhancement and whereas the rest do not have these features and, 
therefore,  will  require  liver  biopsy for  the  diagnosis  of  HCC.  Studies  have compared the 
accuracy  of  CT  and  MRI  for  HCC  diagnosis  by  using  the  explanted  liver  as  the  gold 
standardlxxiv.  (Table  4)  These show that  MRI  is  slightly better  in  the  characterization  and 
diagnosis of HCC when compared with CT scan. The performance of CT and MRI is affected 
by the size of the lesions. Tumors larger than 2 cm, MRI are reported to have accuracy >90%; 
however, in tumors smaller than 2 cm, this level is reduced to 33%.lxxv
Table 4: Comparison in the Accuracy of CT scan and MRI Scan in HCC
Author Gold 
standard
No.
 patient
s
No. 
nodules
HCC 
(n)
CT scan
(Sens/ 
Spe)
MRI
(Sens/ 
Spe)
Burrel et al74 Explanted
 liver
50 127 76 61/66 76/75
Libbrecht 
et al75
Explanted 
liver
49 136 77 50/79 70/82
Hepatic Angiography
With  the  advent  of  CT and  MRI,  the  diagnostic  role  of  hepatic  angiography has 
decreased.  Current  role  of  angiography  is  to  delineate  the  hepatic  arterial  anatomy  in 
planning surgical resection, liver transplantation, embolization or chemoembolization of the 
tumor, or infusion of cytotoxic drugs. The arteries in the tumor are irregular in caliber and the 
smaller branches may show a bizarre pattern.  The hepatic veins fill  early,  and retrograde 
filling of the portal veins results from the presence of arteriovenous anastomoses within the 
tumor.
Pathology
Macroscopic Pathology
Most HCCs arise in cirrhotic  livers and most frequently involve the right  lobe. The 
tumors are typically soft, vary in color from gray green-yellow to light brown, are occasionally 
bile-stained, and often contain foci of hemorrhage or necrosis. The tumors can be single or 
multiple and range from less than 1 cm to more than 30 cm in diameter with a tendency 
toward larger sizes when involving non-cirrhotic livers. The traditional classification of Eggellxxvi 
distinguishes three patterns of HCCs: multinodular, massive, and diffuse. 
• Multinodular HCC typically is associated with cirrhosis 
• In the massive pattern, a solitary tumor mass occupies much of the liver and may be 
associated  with  smaller  satellite  nodules.  This  pattern  has  been  associated  with 
noncirrhotic livers. 
• The diffuse pattern is the least common and is characterized by numerous widespread 
small nodules that mimic cirrhotic nodules and virtually replace the entire liver. 
In cirrhosis, clinically advanced liver disease has been associated with the diffuse or 
multinodular patterns of HCC. HCC may be pedunculated, presumably reflecting an origin 
within an accessory lobe. In more recent macroscopic classifications, HCCs are subdivided 
further  into  two  main  patterns  based  on  growth  characteristics.  Expanding  or  expansive 
tumors have distinct borders that push aside the adjacent liver, and spreading or infiltrative 
tumors have poorly defined borders that microscopically invade the adjacent liver. Nodular 
HCC into an additional three subtypes: 
• Type 1 is represented by HCC presenting as a single nodule
• Type 2 is a single nodule with extranodular growth
• Type 3 has a contiguous multinodular growth pattern
Microscopic Pathology
Hepatocellular carcinoma is classified histologically into well-differentiated, moderately 
differentiated, and undifferentiated (pleomorphic) forms.lxxvii 
Well-Differentiated Appearance 
Most of the tumors are well differentiated and it has 2 varieties, trabecular and acinar 
(pseudoglandular).  In  the  trabecular variety,  the  malignant  hepatocytes  grow  in  irregular 
anastomosing  plates  separated  by  often  inconspicuous  sinusoids  lined  by  flat  cells 
resembling Kupffer cells. The malignant hepatocytes are polygonal, with abundant, slightly 
granular cytoplasm that is less eosinophilic than that of normal hepatocytes. Bile production is 
the hallmark of hepatocellular carcinoma, regardless of the pattern. Gland-like structures are 
present in the acinar variety. 
Moderately Differentiated Appearance
Solid, scirrhous, and clear cell varieties of hepatocellular carcinoma are described. In 
the  solid  variety,  the  cells  usually  are  small,  although  they  vary  considerably  in  shape. 
Pleomorphic multinucleated giant cells occasionally are present. Evidence of bile secretion is 
rare,  and  connective  tissue  is  inconspicuous.  In  the  scirrhous  variety,  the  malignant 
hepatocytes grow in narrow bundles separated by abundant fibrous stroma. In most tumors, 
the  cells  resemble  hepatocytes.  More  often,  tumors  contain  areas  of  clear  cells.  The 
appearance of these cells results from a high glycogen or fat content.
Undifferentiated Appearance 
The  cells  are  pleomorphic  varying  greatly  in  size  and  shape.  The  nuclei  also  are 
extremely variable. Large numbers of bizarre-looking giant cells are present. The cells may be 
spindle-shaped, resembling those of sarcomas. 
Fibrolamellar HCC
Fibrolamellar  HCC, also known as oncocytic HCC or polygonal cell  type HCC with 
fibrous stroma. This subtype is rare in Asia and showed male predominance. The lesions 
most often are large and solitary but may be multiple. The fibrous component often forms a 
central scar that can be demonstrated by radiological techniques. The neoplastic cells are 
larger  than  normal  hepatocytes.  They  are  polygonal  in  shape  and  possess  granular, 
eosinophilic cytoplasm, a so-called “oncocytic” appearance, resulting from numerous swollen 
mitochondria. Pure fibrolamellar HCC has a better prognosis than ordinary HCC because it 
often presents as a surgically resectable lesion, and the fibrous component  is thought to 
result  in a slower rate of tumor growth. The fibrolamellar variant typically occurs in young 
patients with equal gender distribution. It does not secrete alpha-fetoprotein, is not caused by 
chronic hepatitis B or C and almost always arises in a noncirrhotic liver.lxxviii
Fine Needle Aspiration (FNA) of HCC
With  regard  to  HCC,  FNA is  accurate  with  a  sensitivity  rate  of  80  to  95% and  a 
specificity rate of 100%.lxxix  The sensitivity of guided FNA for diagnosing hepatic malignancy in 
most  recent  series  is  90%  to  96%,  with  a  specificity  of  90%  to  100%.  False-negative 
diagnoses of HCC are related either to very well  differentiated tumors that are difficult  to 
identify on the basis of cytology as being neoplastic or to poorly differentiated tumors that are 
difficult to distinguish as hepatocellular in origin.
The presence of at  least two of three criteria (polygonal  cells with centrally placed 
nuclei, malignant cells separated by sinusoidal endothelial cells and bile) was considered by 
Bottles  et  allxxx to  be  97%  sensitive  and  100%  specific  for  HCC  compared  with  other 
malignancies.  Classic HCC is usually graded into well,  moderately or poorly differentiated 
lesions.  Histologic  patterns  comprise  trabecular-sinusoidal,  pseudoacinar  and  solid  types; 
combinations are frequent. 
Cytological Features
• Hepatocytic  characteristics include polygonal  cells  with  well-defined borders,  ample 
granular  cytoplasm,  central  round  nucleus,  well-delineated  nuclear  membrane, 
prominent  nucleolus  and fine,  irregularly granular  chromatin.  Mitoses increase with 
nuclear grade. 
• Cohesive clusters of malignant hepatocytes with arborizing, tongue-like projections of 
broad cords (>2 cells thick) that may be wrapped by peripheral endothelium.
• Well differentiated HCC cells tend to be conspicuous by their small size, monotony, 
subtle increase in N/C ratio and nuclear crowding. Poorly differentiated HCC cells tend 
to be pleomorphic.
• Atypical naked hepatocytic nuclei are seen. Bile may be present within tumor cells or in 
canaliculi or pseudoacini.
• Intracytoplasmic fat and glycogen vacuoles are common. Intracytoplasmic inclusions 
include hyaline, pale and Mallory bodies. Intranuclear cytoplasmic inclusions are seen.
Treatment of HCC
The management of HCC involves multiple disciplines including hepatology, surgery, 
diagnostic  and  interventional  radiology,  oncology,  and  pathology.  Treatment  depends  on 
severity of underlying liver disease, tumor bulk, associated comorbidities and availability of 
expertise in surgical resection, transplantation and ablative therapies. 
Staging of HCC and prognosis
A precise staging of the disease may help decide on prognosis as well as choice of 
therapy with the greatest survival  potential.  There are several prognostic scoring systems 
including  Barcelona-Clinic  Liver  Cancer  (BCLC)lxxxi,  Cancer  of  the  Liver  Italian  Program 
(CLIP)lxxxii, the Chinese University Prognostic Index (CUPI) and Japanese Integrated Staging 
(JIS).
Okuda staginglxxxiii
Negative Positive Stage
Tumor size <50% >50% I: No positive factors
Ascites Absent Present II: 1-2 positive factors
Bilirubin <3 mg/dl >3 mg/dl III: 3-4 positive factors
Serum 
albumin
>3 g/dl <3 g/dl
Strategy for staging and treatment assignment in patients diagnosed with HCC according to 
the BCLC proposal (Fig 2, Table 5)
The BCLC staging and prognostic system accounts for  variables related to tumor 
stage, physical and liver functional status, and cancer-related symptoms and also provides a 
link to a treatment algorithm. Patients in stage A can undergo resection, transplantation, or 
ablation.
Figure 2 
BCLC staging
Table 5 World 
Health 
Organization 
Performance 
Stage
Status grades
Stage 0 Fully active, normal life, no symptoms
Stage 1 Minor symptoms, able to do light activity 
Stage 2 Capable  of  self-care  but  unable  to  carry  out  work 
activities.Up for more than 50% waking hours
Stage 3 Limited self care capacity. Confined to bed or chair >50% 
waking hours
Stage 4 Completely disabled. Confined to bed or chair
CLIP Stage
Points CTP Tumor morphology AFP Portal  vein 
thrombosis
0 A Uninodular ≤ 50% of 
liver
<400 ng/ml No
1 B Multinodular ≤50% of 
liver
≥400 ng/ml Yes
2 C Massive  >50%  of 
liver
The Okuda classification takes into account radiologic tumor size and liver function 
(ascites,  total  serum  bilirubin,  and  serum  albumin)  is  helpful  in  identifying  patients  with 
advanced HCC but may be less adequate for staging patients with early or intermediate stage 
disease.  Another  commonly  used  staging  system  is  the  Cancer  of  the  Liver  Italian 
Program,lxxxiv which uses a mathematical score based on the CTP, tumor morphology, AFP, 
and  presence  of  vascular  invasion;  however,  it  does  not  assess  populations  undergoing 
radical therapies, such as resection or transplantation. Multivariate analysis showed that the 
JIS, CLIP and modified CLIP scores were better staging systems for predicting survival than 
the Japanese and AJCC TNM. Best discrimination ability for patient survival was observed in 
JIS score and CLIP score.lxxxv 
Table 6 Summary of Therapeutic Modalities for HCC and Their Outcomes
Treatment Survival Special issues
Surgical resection 1 y: 97%
3 y: 84%
5 y: 26%–57%
Choice of therapy for patients without 
cirrhosis (low morbidity)
5%–15% of HCC patients eligible
Right hepatectomy has higher risk 
than left hepatectomy
Pre/postresection adjunct therapy not 
recommended
Transplantation 
(LT)
1 y: 91%
2 y: 75%
5 y (MILAN): >70%
5  y  (extended): 
>50%
Curative treatment for chronic 
disease and HCC
MELD exception points for HCC
Effective corresponding to UNOS 
criteria (1 tumor >5 cm; up to 3 
tumors <3 cm
Liver donor LT considered for HCC 
progression outside MILAN criteria
UCSF criteria not implemented in 
current MELD exception allocation 
policy
Radiofrequency 
ablation (RFA)
1 y: 90%
3 y: 74%
5 y: 40%–50%
Effect is more predictable in all tumor 
sizes than following PEI
Superior to PEI in larger tumors; 
equivalent in small tumors 
Requires fewer treatment sessions
Percutaneous 
ethanol injection 
(PEI)
1 y: 85%
3 y: 50%
5 y: 40%–50%
Early HCC patients not suitable to 
resection or OLT or RFA not 
available or contraindicated
Highly effective for small HCC (<2 
cm)
Low rate of AEs
Transarterial
 Chemoembolizatio
n
 (TACE)
1 y: 82%
2 y: 63%
Nonsurgical patients with 
large/multifocal HCC w/o vascular 
invasion or extrahepatic spread
Surgical resection: 
Only about 5% of the patients with HCC in Western countries and nearly 40% of 
patients in Asian populations are candidates for surgical resection. Resection is the treatment 
of choice for noncirrhotic patients who have HCC. The 5-year survival rate after resection can 
exceed 50%.lxxxvi lxxxvii Patient selection is the most important to achieve a long-term response. 
Those who have Child’s  class  A cirrhosis,  normal  bilirubin  levels,  no  portal  hypertension 
(hepatic venous pressure measurements >10 mm Hg), and no varices, the 5-year survival 
rate reaches 70%.lxxxviii The presence of single tumors smaller than 5 cm is a favorable factor 
for resection because the risk of vascular invasion and dissemination decreases. The most 
important  predictors  of  recurrence  are  microvascular  invasion  and  multinodular  tumors. 
Recurrence rates of 50%at 3 years and 70% at 5 years are seen after resection, but these 
rates are significantly lower when the favorable characteristics are present.85
Local ablation
Those who are at early stage HCC and not suitable for resection or OLT are the best 
candidates for local ablation. Ablation may be achieved by chemical (100% ethanol or 50% 
acetic acid) or physical (radiofrequency, cryoablation, or microwave) techniques. The efficacy 
of  percutaneous ablation is  assessed by CT or  MRI  1 month after  the procedure and is 
indicated by the absence of contrast within the tumor. The recurrence rate is as high as that 
for resection.85 Percutaneous ethanol injection is the most widely used ablation approach with 
the necrosis rate for HCC smaller than 2 cm is 90% to 100% but is reduced to 70% in tumors 
between 2 cm and 3 cm and is 50% in tumors between 3 cm and 5 cm. lxxxix xc A long-term 
study showed that with successful tumor necrosis the survival rate in Child’s class A disease 
may reach 50% at 5 years.xci       The potential drawback of ethanol ablation is the need for 
repeated sessions (average of four per patient) to achieve complete necrosis. 
An alternative ablative technique is radiofrequency ablation. It involves the insertion 
of  single  or  multiple  electrodes that  deliver  heat  around the  tip  leading a wide  region of 
necrosis.  The efficacy of  radiofrequency ablation  is  similar  to  that  of  ethanol  ablation for 
tumors smaller than 2 cm, but the technique requires only one session instead of four. The 
efficacy for tumors larger than 2 cm is better than that of ethanol ablation.xcii xciii Importantly, 
radiofrequency ablation has been shown to provide better  local  control  of  disease and is 
associated  with  better  survival  than  ethanol  ablation.  The  one  potential  drawback  of 
radiofrequency ablation is a higher rate of adverse events such as pleural effusion, pain, and 
peritoneal bleeding. It is the ablative procedure of choice in most centers.
Transarterial chemoembolization
HCC is a highly vascular tumor that derives most its blood supply from the hepatic 
artery, whereas the rest of the liver is perfused by both the hepatic artery and the portal vein. 
Hence  selective  intra-arterial  administration  of  chemotherapeutic  agents  followed  by 
embolization of the major tumor artery has been performed to treat HCC. This procedure may 
be complicated by liver failure, possibly by the ischemic infarct of adjacent non-tumorous liver. 
There was a survival benefit observed in a meta-analysis with TACE versus control but no 
survival benefit with embolization alone versus control. A recent randomized study compared 
TACE versus supportive care in 112 patients who had unresectable HCCxciv. Two thirds of the 
patients had multinodular tumors with a maximal tumor diameter of about 5 cm. Only TACE 
showed a survival  benefit  compared with conservative treatment (hazard ratio,  0.47; 95% 
confidence interval, 0.25–0.91). The tumor-free survival rate at 2 years was 63% for TACE 
and 27% for  conservative management.  These studies showed that  TACE can lead to  a 
survival  benefit  in  carefully  selected  patients  who  have  compensated  or  mildly 
decompensated liver function (78% in Child’s class A patients and 22% in Child’s class B 
patients), absence of tumor-related symptoms, renal failure, or portal vein invasion, and a 
maximal tumor diameter of about 5 cm.
Systemic chemotherapy/radiation/hormonal therapy
A variety of chemotherapeutic regimens have been used for patients who have HCC 
not amenable to any of the treatments discussed above. The results have been dismal and 
may be related in part to the limitations in choice of chemotherapeutic agents and the dose 
that can be used in patients who have underlying cirrhosis. Focal liver radiation targeted to 
the tumor has been shown to result in complete responses in 17% to 92% of unresectable 
HCC but is most effective in smaller lesions. About one third of patients develop radiation-
induced liver damage, which may lead to hepatic decompensation.xcv There have been no 
randomized, controlled trials comparing radiation against local ablation or chemotherapy. 
A new form of radiation therapy, direct intratumoral injection of Yttrium-90 spheres 
(TheraSphere) has been reported to result in complete destruction of nonresectable HCC.xcvi 
This technique needs to be evaluated further in randomized clinical  trials as to whether it 
improves overall survival. Tamoxifen, chemotherapy, anti-androgens, and octreotide do not 
have efficacy or improve survival for HCC. 
Liver transplantation
OLT is the best treatment option for HCC because it eliminates the tumor together 
with the entire diseased liver, thereby eliminating the risk for development of de novo HCC. In 
the early 1990s the results of OLT for HCC were dismal, with 1-year survival rates of 10% to 
70% and  3-year  recurrence  rates  up  to  69%.xcvii Mazzaferro  and  colleagues  published  a 
landmark paper on OLT for HCC.xcviii When OLT was restricted to patients who had a single 
tumor of 5 cm or less and no more than three tumors, each less than 3 cm in diameter, the 4-
year  survival  rate  was  75%,  and the  recurrence-free  survival  rate  was  83%.  For  the  35 
patients (73%) who met the predefined criteria, the overall and recurrence-free survival rates 
were 85% and 92%, respectively. In the 13 patients (27%) who had tumors exceeding the 
criteria, the overall survival rate was 50%, and the recurrence-free survival rate was 59%. The 
United  Network  for  Organ  Sharing  (UNOS)  has  adopted  these  criteria.  The  number  of 
available donors worldwide and therefore only a finite number of transplantations for HCC will 
be performed. In addition, waiting time for liver transplants is increasing worldwide, from 6 
months to more than a year. Therefore, some patients will not be able to proceed to OLT 
because  of  tumor  progression  or  deterioration  in  medical  condition.  A  recent  study from 
Barcelona showed a decrease in survival rate from 84% to 54% as the waiting time to OLT 
increased from 62 to  162 days.xcix In  the  United States,  patients  who have HCC receive 
higher-ranking scores to shorten their waiting time and to prioritize them. The impact of the 
adjusted score on the post transplantation survival of patients who have HCC and the wait-list 
mortality of patients who have non-HCC end-stage liver disease remains to be determined.
The size limitations described by Mazzaferro et al95 have been challenged. The group 
in San Francisco reported 1- and 5-year survival rates of 90% and 75%, respectively. Twenty-
five percent of these patients had solitary tumors 5 cm to 6.5 cm in diameter or fewer than 
three tumor nodules, each smaller than 4.5 cm and with a total diameter less than 8 cm.c 
These data were based on the size of the tumor at the time of explants examination not on 
size  at  diagnosis  when  the  decision  to  transplant  is  planned.  The  authors  suggested 
loosening the criteria of OLT for HCC, but these results should be confirmed by other centers 
before  changing  the  current  criteria.  Live-donor  transplant  potentially  can  eliminate  the 
significant waiting time and allow the surgery to be performed electively. A recent case series 
from Japan described 56 patients who underwent live-donor transplantation for HCC.ci The 1- 
and 3-year survival rates were 73% and 55% respectively, and six tumor recurrences were 
noted. The authors concluded that the 3-year survival rate was lower than that in patients who 
underwent live donor transplantation for nonmalignant liver disease (73%). However no data 
available the expansion of the criteria determined by Mazzaferro95 for those receiving live-
donor transplants for HCC. 
Molecular therapies in HCC 
Most of the treatments aim to abrogate signaling pathways related to proliferation and 
cell survival. Alternatively, other treatments rely on the blockade of growth factors and signals 
related to dissemination of the disease (e.g. angiogenesis, telomerase activation) etc. Most of 
the agents currently under investigation block membranous tyrosine kinase receptors (TKRs). 
The ligands for these receptors include EGF, PDGF, VEGF, and HGF. (Table 7)
Table 7 Molecular targeted therapies assessed in clinical trials in HCCcii
Treatment Type molecule (target)
Sorafenib Small molecule (TKI)
RAF, VEGF, PDGFR
Erlotinib Small molecule (TKI)
EGFR inhibitor (TKI)
Cetuximab Monoclonal antibody (Mab)
EGFR inhibitor
Lapatinib Small molecule (TKI)
EGFR, Her2/nu
Sunitinib Small molecule
PDGFR, VEGFR, KIT (KI)
Bevacizumab Monoclonal antibodies
VEGF (Ab)
Sorafenib 
Sorafenib is an oral multikinase inhibitor with activity against several tyrosine kinase 
(VEGFR2, PDGFR, c-Kit receptors), and serine/threonine kinases (b-Raf). This drug targets 
two  of  the  main  pathways  involved  in  hepatocarcinogenesis  by  blocking  angiogenesis 
(VEFGR2 and  PDGFR)  and  cell  proliferation  through  activation  of  Ras/MAPKK signaling 
(bRAF).ciii Sorafenib increases progression free survival in renal cancer and has recently been 
approved for use in the management of this cancer. 
The randomized phase III double-blind placebo-controlled clinical trialciv conducted in 
patients with advanced HCC treated with sorafenib has shown improvement in survival of 3 
months  in  patients  with  advanced  HCC,  which  was  not  only  statistically  significant.  The 
median overall survival was 10.7 months with sorafenib and 7.9 months with placebo (hazard 
ratio  for  death,  0.69;  95%  confidence  interval,  0.55–0.87;  p  <  0.001).  Median  time  to 
progression was 5.5 months with sorafenib vs. 2.8 months with placebo (hazard ratio 0.58; 
95% confidence interval 0.45–0.74; p < 0.001). Recently, the drug has been approved both by 
the FDA and EMEA for  the treatment  of  HCC. Sorafenib  is  the first  systemic therapy to 
prolong  survival  in  HCC and,  consequently,  is  the  new  reference  standard  treatment  of 
patients with advanced HCC.
End of Literature Review
Materials and Methods
This descriptive study was carried out in the Department of Medical Gastroenterology, 
Madras Medical College, Chennai. This is the major referral tertiary care center available to 
the  population  of  Tamilnadu,  Pondicherry  and  neighboring  states  Andhra  Pradesh  and 
Karnataka. The main aim of our study was to assess the clinical and laboratory parameters in 
patients  with  hepatocellular  carcinoma.  The  study  was  carried  between  the  periods  of 
February 2007 to January 2009. (24 months)
Inclusion Criteria
• Patients who are attending Department of Medical Gastroenterology with clinical 
diagnosis of Hepatocellular carcinoma. Cases were included if they met EASL 
diagnostic criteria for HCC.67
Diagnostic criteria for HCC
Cyto-histological criteria
Non-invasive criteria (restricted to cirrhotic patients)
1. Radiological criteria: two coincident imaging techniques*
Focal lesion >2 cm with arterial hypervascularization
2. Combined  criteria:  one  imaging  technique  associated 
with AFP
Focal lesion >2 cm with arterial hypervascularization
AFP levels >400 ng/ml
Exclusion Criteria
• Patients who have been diagnosed as 
1. Hemangioma of liver
2. Secondaries liver
3. Benign focal liver disorders
II. Study protocol
At the time of admission a detailed history was obtained from the patients or care giver. 
Their  details  entered  in  a  preformed  proforma.  (Annexure)  They  were  enquired  about 
presenting complaints, the duration of illness, past h/o jaundice, blood transfusion. Detailed 
history of alcoholism and status of chronic liver disease and their treatment details obtained. 
Patients were carefully examined at the time of admission. Various clinical parameters 
studied which include jaundice, pallor, stigmata of chronic liver disease. Enlarged liver was 
looked for size, surface, border and bruit. Splenomegaly, free fluid and neurological status 
were  assessed.  Stage  of  the  liver  disease  assessed  based  on  Child-Turcotte-Pugh 
Classification. 
Child-Turcotte-Pugh Classificationcv
Parameter Numerical Score
1 2 3
Ascites None Slight Moderate/severe
Encephalopathy None Slight/moderat
e
Moderate/severe
Bilirubin (mg/dL) <2.0 2-3 >3.0
Albumin (g/dL) >3.5 2.8-3.5 <2.8
Prothrombin time 
(seconds increased)
1-3 4-6 >6.0
The clinical  stage and the severity of the disease were assessed based on Okuda 
stage and CLIP score.82
Okuda staging83
Negative Positive Stage
Tumor size <50% >50% I: No positive factors
Ascites Absent Present II: 1-2 positive factors
Bilirubin <3 mg/dl >3 mg/dl III: 3-4 positive factors
Serum 
albumin
>3 g/dl <3 g/dl
CLIP Stage82
Points CTP Tumor morphology AFP Portal  vein 
thrombosis
0 A Uninodular ≤ 50% of 
liver
<400 ng/ml No
1 B Multinodular ≤50% of 
liver
≥400 ng/ml Yes
2 C Massive  >50%  of 
liver
All  the patients enrolled in the study were investigated as outlined in the Proforma 
(Annexure).  Patients  were  subjected  for  radiological  investigations  include  ultrasound 
abdomen, Contrast enhanced Computed tomography (CECT) abdomen or MRI, whichever is 
feasible. Blood samples were collected for viral markers such as HbsAg, anti-HCV antibody, 
HIV serology, Liver function tests, and serum alpha fetoprotein (AFP). Ascetic fluid collected 
for  biochemical,  cytological  investigations.  Upper  GI  endoscopy was  done  to  assess  the 
grade  of  varices  and  any evidence of  portal  hypertension.  After  admission,  once  clinical 
diagnosis was made appropriate therapy was instituted. USG guided Fine needle aspiration 
and trucut biopsy was performed whenever is feasible and if not contraindicated. 
Contraindications for FNAC/ trucut biopsy
1. Impaired hemostasis with prothrombin time more than 3 seconds over control,  PTT 
more  than  20  seconds  over  control,  thrombocytopenia  and  markedly  prolonged 
bleeding time
2. Severe  anemia  (Hb  <8  g/dL)  /Septic  cholangitis/  Possible  hemangioma/  Possible 
echinococcal (hydatid) cyst
3. Local infection near needle entry site, such as right sided pleural effusion or empyema, 
right lower lobe pneumonia, local cellulitis, infected ascites or peritonitis
4. Tense ascites (low yield technically, risk of leakage). High-grade extrahepatic biliary 
obstruction with jaundice (increased risk of bile peritonitis)
5. Uncooperative patient/ Poor performance status
Patient preparation
Procedures  and risks  of  the  procedure  were  explained and informed consent  was 
obtained. All  aspirin products and non steroidal agents were discontinued at least 5 days 
beforehand. Injection vitamin K was given in jaundiced and liver failure patients. The patients 
were  kept  in  empty  stomach  after  midnight,  the  day  prior  to  the  procedure.  Screening 
laboratory studies include CBC, PT/PTT, BUN, bleeding time, coagulation time and typing 
and cross matching for possible transfusion.  
EQUIPMENT: Disposable automated Trucut biopsy gun –18 Gauge needle with 2 cm throw 
length, designed to cut out cores of tissue. Specimens obtained with this needle were less 
fragmented, even in the cirrhotic liver and thus a high success rate. Specimen was obtained 
using suction/aspiration into a 10 ml syringe. Trucut needle is a modernized Vim-Silverman 
needle. 
Technique 
Patient was laid supine in bed with right hand behind his head. Liver margins were 
estimated by ultrasound. Two approaches are popular, transthoracic (intercostal) or subcostal 
(anterior). With the former, biopsy site is identified along the midaxillary line in the center of 
hepatic dullness; usually the eighth or ninth intercostal space. This approach avoids other 
abdominal organs but always penetrates the pleura. With the subcostal approach, the biopsy 
site lies below the costal margin and is used when a liver mass is easily palpable below the 
right costal margin. The risk of visceral laceration is higher and this approach is infrequently 
used.
A wide area was prepped and draped in sterile fashion. The skin was anaesthetized 
with  1% lidocaine,  and  then  deeper  structures  such  as  subcutaneous  tissue,  intercostal 
muscles and diaphragm were infiltrated in that order. A small superficial incision was made 
with a No 11 blade at the needle entry site to facilitate needle insertion. The first needle pass 
should sample the centre of  the lesion since this will  reduce contamination by cells from 
surrounding normal  liver.   The centres of  large lesions may occasionally be necrotic and 
hence may not render diagnostic material.  If the first pass yielded only necrotic debris and/or 
inflammatory cells, the second pass should be made close to the edge but well within the 
target. Under US guidance, an outer guide needle of larger diameter and 10 cm long was first 
introduced  through  the  superficial  layers.  This  outer  needle  will  not  only  ensure  needle 
stability, but will also allow multiple passes of the needle without inconvenience to the patient. 
The fine needle of 20 gauge was attached to a disposable syringe and was passed through it. 
When the  tip  of  the  fine  needle  was  correctly  located  within  the  lesion  by US,  negative 
pressure was applied and the needle advanced steadily for 1-2 cm and moved back and forth. 
With the needle still in position negative pressure was released and needle withdrawn. The 
patient was asked to suspend respiration during advancement of the needle. Usually several 
passes of the needle were performed in slightly different directions to ensure representative 
sampling.  The  material  in  the  needle  was  expelled  on  to  glass  slides  and  smeared 
immediately.
Through the outer needle, 18 gauge automated biopsy gun of 2 cm throw length was 
inserted and patient asked to suspend respiration. The position of the stylet was confirmed by 
US and then the device was fired. A 2.5 cm core of liver was aspirated and needle withdrawn. 
Several passes of the biopsy needle (2-3) were performed to minimize sampling bias.
Specimen: At least two to three liver cores, each more than 2 cm in length was routinely fixed 
in 10% buffered formalin, specimen processed and the tissues stained with  hematoxylin and 
eosin.Cytological  preparation  -  fluid  from  aspirating  syringe  was  smeared  on  clean 
microscope slides and sent to Cytology Laboratory. Smears were air-dried and stained with 
May-Grunwald-Giemsa as well  as fixed in 95% alcohol  and stained by  hematoxylin  and 
eosin. 
Aftercare
Patients were monitored in a recovery area with frequent examination of vital signs 
(blood pressure, pulse) post biopsy. If no complications were apparent, they were transferred 
back to ward in stretcher. Strict bed rest was enforced for 24 hours. For the first 2 hours, 
patient  was  positioned  on  his  right  side.  Vital  signs  were  checked  frequently.  Diet  was 
restricted to clear liquids for several hours, then full liquids as tolerated. Acetaminophen was 
usually sufficient for pain control. All patients signed informed consent prior to aspiration and 
the  study protocol  conformed to  the  ethical  guidelines  of  the  Declaration  of  Government 
General  Hospital,  as  reflected  in  a  prior  approval  by  the  Hospital’s  Human  Research 
Committee. Patients were followed with serum alpha fetoprotein and radiological methods. 
Statistical methods:
The quantitative data were presented as mean±SD or median (range). The continuous 
variables between the two groups were compared by the Mann–Whitney U-test. The Kruskal–
Wallis test was used to compare a continuous variable across different stages of tumors. The 
P-value<0.05 was considered significant.
Results
Baseline characteristics 
Seventy two patients who fulfilled the study criteria were included in the present study. 
Table 1 reveals that the mean age was 54 years with male female ratio of 3:1. (Figure 2) 
Asymptomatic hepatocellular carcinoma (HCC) observed only in 2 cases. Preadmission mean 
duration of illness was 54 days. Twenty two percent of patients had cirrhosis, of which only 7 
were known cases of cirrhotics at admission. 
Age distribution
The age distribution among the study population is summarized in Fig 1. Nearly half of 
the patients belong to the age group of 60 to 70 years.  Nearly 15 percent of patients either 
belong to 30 -40 years or more than 70 years of age. 
Clinical features at presentation
Among the symptoms abdominal pain and weight loss was most commonly observed 
symptoms. (Table 2, Figure 3 & 4) More than half of the patients had anorexia and or weight 
loss.  The  features  of  hepatic  decompensation  were  seen  in  half  the  patients  at  first 
presentation with ascites in 56.9%, jaundice in 22.2% and hepatic encephalopathy in 4.2% of 
patients. Gastrointestinal bleed melena was present only in 1.4% patients. Hepatomegaly was 
seen in more than half the patients (81.9%) while in 18% of cases liver was not enlarged. The 
enlarged liver was hard in two-third cases and was firm in consistency in the remaining one-
third.  Clubbing,  hepatic  bruit  and were  less  common.  Abdominal  lump as  a presentation 
observed in 12.5% of patients. 
Table 1 Baseline characteristics of patients with HCC 
Parameters N = 72
Age (years)
Median (range) 55 (30–75)
Mean± SD 54±12
Mode 60
Sex (M : F) 54:18 (3:1)
Symptomatic HCC (%) 97.2
Incidental HCC (%) 2.8
Symptom duration before HCC diagnosis 
(days)
Median (range) 30 (3–240)
Mean±SD 54±50
<1 month (%) 40.2
>1 month (%) 59.8
Known cirrhotic at diagnosis—no. (%) 7 (9.7)
Underlying cirrhosis at diagnosis—no. (%) 16 (22.2)
Table 2 Clinical profile of HCC
Symptoms (%) Physical signs (%)
Abdominal pain  66.7 Hepatomegaly 81.9
Anorexia 56.9 Pallor 61
Weight loss  66.7 Edema 37.5
Jaundice  22.2 Icterus 25
Fever 6.9 Palpable spleen 22.2
Encephalopathy 4.2 Hepatic bruit 18.1
GI Bleed 1.4 Clubbing 2.8
Ascites 56.9 Abdominal lump 12.5
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Figure 3 Symptoms of HCC
Figure 4 Physical Signs
Hematological, biochemical and endoscopic profile 
The biochemical investigations were mildly deranged. Serum alpha fetoprotein (AFP) 
was diagnostic  (>400 ng/ml)  in  43  of  70  (61.5%) patients;  with  normal  AFP in  14 of  70 
(18.5%) patients. The median serum AFP value was 515 ng/ml (range 1.3–92625) (Table 3). 
Mean AST and ALT values were more than two time of upper limit of normal. The mean 
serum bilirubin  was 2.6±3.  More than three fourth  of  cases had esophageal  varices with 
gastric varices of 8.3%. Nearly three fourth of cases had low serum albumin level of <2.8 gm
%. 
Etiological studies
The etiologic  work up was available  only in 52 (72%) patients,  while in  rest  of  20 
patients (27.7%) etiology was unknown due to incomplete investigation reports. HBV was the 
most  common  viral  etiologic  agent  associated  with  HCC,  observed  in  23  of  52  (31.9%) 
patients either alone or as cofactor with alcohol or HCV (Table 4). Alcohol or HCV alone as an 
etiological agent was observed in 20.8% and 9.7% of cases respectively. Dual infection was 
observed only in one patient along with alcohol abuse. (Table 4)
Radiological studies
Radiological profile was analyzed from both US and CT scan regarding number, size, 
distribution and characteristics of liver lesions along with vascular details and metastases. 
(Table 5) Contrast enhanced CT scan abdomen was available for 61 of 72 cases. The HCC 
most  commonly noted  in  the  right  lobe of  liver  (48.6%),  followed by bilobar  involvement 
(34.7%). The left  lobe was involved in approximately one fifth of  cases. Multicentric HCC 
involving either one lobe or both lobes were seen in 43% of patients. 
Table 3 Hematological, biochemical and endoscopic profile of HCC
Parameter Mean ±SD Median (range)
Hemoglobin (g/dl) 10.2±1.9 10 (3-14)
ESR 35.1±28.8 29.50 (5-182)
Serum bilirubin (mg/dl) 2.6±3 1.6 (0.5-2.6)
Serum albumin (g/dl)
<2.8 g/dl (%) 20.8
2.8–3.5 g/dl (%) 40.3
>3.5 g/dl (%) 38.9
AST (IU/l) 96.8±78.4 80.5 (0.9-425)
ALT (IU/l) 92.5±78.9 61 (17-394)
SAP (IU/l) 280±291 201.5 
(22-1898)
Serum AFP (ng/ml) (n=70)* 8980±18372 515 
(1.3-92625)
<10 ng/ml 20
10–400 ng/ml 18.5
>400 ng/ml 61.5
Upper GI endoscopy (n=48)*
Esophageal varices (%) 79.2
Gastric varices (%) 8.3
Portal hypertensive
Gastropathy (%)
12.5
*Number of patients in whom the investigation was done.
Table 4 Etiological work up of HCC
Etiology No (%)
HBV related (n=52)* 23 (31.9)
HCV related (n=50)* 7 (9.7)
Alcohol alone 15 (20.8)
HBV+HCV 1
Alcohol +HBV 6 
Alcohol +HBV+HCV 1
Alcohol +HCV 4
*Number of patients in whom the investigation was done.
 Very large tumors (>5 cm) were seen in two-third of cases. The average size of HCC 
was 6±4 cm. Small HCC (<2 cm lesion) was seen in only 6% of patients approximately. Single 
lesion was the most common presentation of  HCC observed in two-third cases. Three or 
more lesions were seen in about one-fifth of cases. The hyperechoic (42.7%) or hypo echoic 
(39.2%) lesions were the most common appearance on US observed in 80% of the cases. 
Similarly, the CT appearance of HCC was hypo dense in 21.4%, mixed or heterogeneous 
density in 52.4% and hyper dense in 26.2% patients. Vascular invasion of either major branch 
of splenoportal axis was seen in one fifth of the patients. Main trunk of portal vein or its main 
branches  were  involved  in  20.8% patients.  Extrahepatic  spread  of  tumor  was  seen  in  6 
patients. Metastases involving retroperitoneal lymph nodes were seen in 3 of 6 patients (50%) 
followed by lung and pleural and left supraclavicular lymph node metastases in one each. 
Histopathological study
Fine needle aspiration (FNA) and liver biopsy was available in 36 patients. Diagnosis 
of HCC was made based on cytohistology in 31 (86.1%) patients. In five patients (13.8%) 
cytohistology was  normal.  Nearly  three  fourth  had  well  differentiated  histology.  No major 
complication or fatality was reported in any of these patients except mild pain at the site of 
needle puncture in few. (Table 6, Figures 5, 6,7,8)
Table 5. Tumor characteristics of hepatocellular carcinoma patients
Characteristics Patient number (%)
Localization of tumor
Right lobe 35 (48.6)
Left lobe 12 (16.7)
Both lobes 25 (34.7)
Single tumor 41 (56.9)
Multiple tumors 31 (43.1)
Tumor size 
<3 cm 11 (15.3)
3–5 cm 15 (20.8)
>5 cm 45 (62.5)
US appearance of HCC (n=71)
Mixed-echo or 
heterogeneous 
12 (17.7)
Hypoechoic 28 (39.2)
Hyperechoic 30 (42.7)
Isoecho 1 (1.4)
CT appearance of HCC (n=61)*
Hypodense 13 (21.4)
Mixeddensity or 
heterogeneous 
32 (52.4)
Hyperdense 16 (26.2)
Portal vein thrombosis 
No portal vein thrombosis 57 (79.2)
Main portal vein thrombosis 14 (19.4)
Right portal vein thrombosis 1 (1.4)
Table 6 Histopathological profile of HCC (n=36)*
N=36 (%)
Total no Cytology & 
histopathology positive cases
31 (86.1)
Well differentiated 25 (69.4)
Poorly differentiated 6 (16.6)
*Number of patients in whom the investigation was done
Figure 5 Hepatocellular Carcinoma –FNA
 Showing malignant hepatocytes with Endothelial Rimming (100x)
Figure 6 Hepatocellular Carcinoma –FNA 
Showing Nuclear Pleomorphism & intranuclear inclusions (400x)
Figure 7 Hepatocellular Carcinoma-HPE (100x)
Figure 8 Hepatocellular Carcinoma-HPE (400x) Showing 
trabecular pattern and polygonal hepatocytes  with increased
 pleomorphic hyperchormatic nuclei
Figure 9 CECT Abdomen showed contrast enhanced lesion 
noted in the left of the liver
Figure 10 MRI abdomen showed marked hepatomegaly with large fat containing 
heterogeneous hypervascular mass in segment 5 & 8
Staging of HCC
Based on clinical, radiological and laboratory investigations both Okuda staging and 
CLIP score was done. Okuda staging was possible in only 70 patients. More than three-fourth 
of HCC was in Okuda stage 2 (72.8%). Only five patients had Okuda stage 1 lesion. (Table 7, 
Figure 9)  The size of HCC lesion was >5 cm in 73% of cases. Hence, HCC was large and 
very advanced in most of the cases (Table 6). More than ninety percent of patient had CLIP 
score of ≥2.The serum AFP was not related to different stages of Okuda and CLIP Score (P 
>0.05, NS).
 Table 7 Okuda and CLIP staging of HCC and its correlation with serum AFP (n=70)
No (%) AFP (ng/ml)
 Median (range)
P value
Okuda stage
I (n=5) 6 (2.9-60000)
II (n=51) 515 (1.3-92625)
III (n=14) 628.5 (7.3-50000)
>0.05*
CLIP score
0 (n=7) 6 (2-54)
1 (n=24) 515 (1.3-58452)
2 (n=17) 727 (3.65-60000)
3 (n=12) 497 (7.3-92625)
4 (n=8) 10295.5 (1500-43000)
5 (n=1) 420
6 (n=1) 690
>0.05*
* Statistically not significant.
Figure 9 Okuda staging
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Discussion
Hepatocellular  carcinoma (HCC) is  one of  the most  frequent  neoplasms worldwide 
causing increased morbidity and mortality.  The incidence of HCC increases with age. The 
development of HCC is uncommon before 40 years of age in western world. However, the 
pattern of HCC incidence by age is sometimes dependent on the geographic pattern or on 
etiologic factors.5 
The age distribution of patients with HCC in the present study was similar to other 
studies in past. Studies from India have shown the maximum incidence of HCC in the fifth to 
sixth decade.cvi cvii Our study showed that 43 percent of cases belong to 60 to 70 years of age. 
Only 15% belongs to 30 – 40 years age group. A very similar observation made by Saini et 
al.34 In our study, HBV-related HCC occurs in older age group as compared to HCV-related 
HCC. This is in contrast to the earlier observations that HCV related HCC observed in older 
age groups, i.e. at sixth decade. 8, 9 
HCC commonly observed in male sex. The male preponderance is similar to other 
studies.12,  cviii The population-based data show a male to female ratio of 3:1–2:1.1.cix In our 
study showed male female ration of 3:1. High preponderance of HCC in males in our study 
could  be  due  to  gender  bias  in  seeking  medical  treatment.  And  this  could  be  partially 
explained by the fact that men are more likely to be infected with HBV and HCV, consume 
alcohol, smoke cigarettes, and have increased iron stores.4 Hospital based data from various 
studies made similar observation.35
The overall  clinical  presentation of  HCC patients  in  our  study was similar  to  other 
studies.34,  35 Asymptomatic  HCC observed  only  in  two  of  our  patients.  Low incidence  of 
asymptomatic HCC detection possibly could be due to referral bias or possibly due to non 
availability of screening programs for the high risk groups. In a series of 461 Italian patients, 
asymptomatic  HCC  was  detected  in  23%.63    Hepatic  decompensation  as  presentation 
observed  in  56%  of  our  patients.  New-onset  ascites,  recurrent  variceal  hemorrhage,  or 
progressive encephalopathy should always raise suspicion for HCC. Abdominal pain was one 
of the most frequent manifestations in patients with HCC is reported in 66.7% of our patients. 
Pain abdomen was reported as a feature in 46% of Japanese115 and 90%–95% of African114 
patients with HCC. Acute onset pain may also reflect intraperitoneal bleeding, may present as 
an acute abdomen — this is one of the most dramatic and life threatening presentations of 
HCC. This type of presentation not observed in any of our cases. In sub-Saharan Africa and 
Southeast Asia, spontaneous rupture of  HCC is the most common cause of spontaneous 
hemoperitoneum, with an incidence of approximately 10% of patients with HCC.cx Less acute 
bleeding is much more common in patients with advanced HCC; and at the time of autopsy, 
more  than  50%  of  patients  have  blood-stained  ascites.cxi A  similar  presentation  of 
hemorrhagic ascites noted in 11.1% of our cases, of which, 2 had only hemorrhagic ascites 
as a major clinical presentation. 
The incidence of gastrointestinal bleed was 1.4% in the present series. Kumar et al 
reported 20% of their cases presented with varices bleed, whereas the other series quoted 
the incidence of 2-7.6%.114,  115   Yeo  et alcxii reported that varices represent the source of 
bleeding in only half of the HCC patients presenting with gastrointestinal bleeding; in those 
patients with non-variceal bleeding, duodenal ulceration is the most common cause.
Jaundice represents an important clinical presentation of HCC was observed in 22.2% 
of  our cases,  but  reported incidence vary from 5% to 44% in earlier  studies.cxiii Jaundice 
complicating HCC has been classified into one of two types.112 The hepatocellular type (90%), 
related to extensive tumor infiltration of a cirrhotic liver. These patients have a grim prognosis, 
with 90% of them dying within 10 weeks of their first clinical presentation. Other rare causes 
of jaundice include reactivation of the underlying viral hepatitis, and alcohol- or drug-induced 
hepatitis. Patients with type 1 obstructive jaundice have an intraluminal obstruction by a tumor 
thrombus. Biliary obstruction due to clot formation secondary to hemobilia of the biliary tree is 
typical of a type 2 obstruction. Type 3 obstruction is characterized by extraluminal neoplastic 
compression of the biliary tree. The paraneoplastic syndrome was not reported in our case 
series. Kumar et al35 reported only one patient developed troublesome hypoglycemia. The 
incidence of paraneoplastic syndromes especially hypoglycemia has been reported in up to 
30% cases. The rarity of paraneoplastic syndrome has been seen in other Indian series as 
well.12, 106 
Underlying cirrhosis was seen in 31.9% of our HCC patients.  HCC with underlying 
cirrhosis reported in 70–86% of Indian autopsy series and the clinical studies observed 30–
80% of cases.11, 12 The present study is in conformity with the previous studies from India.12, 34 
However, some cases of cirrhosis might have been missed in the present study, as evidence 
of cirrhosis may not have been strictly looked for in all cases.
Frequency of Clinical Features of HCC
Clinical data South Africacxiv Japan cxv Italy63 India 35 Current series
Abdominal pain 95 46.2 38 68 66.7
Anorexia 25 44.7 6.7 74 56.9
Weight loss 34 28.9 8 55 66.7
Ascites 51 26.5 17.5 51 56.9
Fever 35 16.7 12 36 6.9
Jaundice 28 16.7 14 35 22.2
Variceal 
bleeding
2 7.6 4 22 1.4
Hepatomegaly - - 90 84 81.9
Palpable mass 92 23.3 - - 12.5
Ankle edema - 16.8 - 37.5 37.5
Asymptomatic - - 38 - 2.8
The HBV is the most common etiologic factor in Asian countries. It accounts for up to 
three-fourth cases of HCC, while HCV infection may account for 10–15% of HCC cases.cxvi cxvii 
cxviii HbsAg positivity in our cases was 31.9%, which is comparable with other Indian studies 
(36% to 74 %).10, 11, 31  The prevalence of anti-HCV antibody in Indian population varies from 
0.3% to 1.8%.cxix In our case series HCV positivity noted only in 9.7% of cases. However, 
PCR-based  studies  have  found  HCV  RNA  positivity  in  27–33%  of  patients  with  HCC. 
Serological evidence of HCV infection in patients with HCC in India is 15%.12 Dual infection 
with  or  without  alcohol  was  seen in  2% of  patients,  similar  lower  incidence observed  in 
previous studies.12, 35 
India, despite being an intermediate endemic zone for HBV has low incidence of HCC 
unlike other Asian countries. This phenomenon is akin to low HCC incidence in Greenland 
Eskimos as compared to Alaskan Eskimos despite similar HBsAg positivity.cxx However, in a 
proportion of patients the etiology was unknown due to incomplete work up or absence of 
markers for either HBV or HCV and alcohol. This is because of as patients may not have 
been aggressively investigated, once an advanced lesion was detected ruling out curative 
therapy in most. An earlier prospective study, the patients with unknown etiology constituted 
almost  20% of  patients  despite  aggressive  work up including for  p53 gene mutation and 
dietary contamination with aflatoxin B.12 Such a high proportion of HCC patients without a 
known etiologic  factor  may point  to  the  possibility  of  another  hitherto  unknown  factor  or 
pathogenetic mechanism for HCC in India and needs further study.
Sensitivity of AFP ranges from 39% to 64%, specificity 76–91% and positive predictive 
value 9–32%.69,  cxxi These figures possibly suggest that the serum AFP estimation may not a 
good screening tool for HCC. As per the diagnostic criteria adopted by EASL, serum AFP 
>400 ng/ml was present in only 61.5% cases. More than two third (61.5%) of our patients had 
elevated AFP values beyond diagnostic level. Others had either normal level (20%) or levels 
were in non-diagnostic range (18.5%). There are many studies available showing that, serum 
AFP is frequently elevated in patients with liver cirrhosis without HCC and can be normal or 
only moderately elevated in patients with hepatocellular carcinoma.cxxii The median AFP level 
was only 515 ng/ml in the study population despite advanced HCC was noted in three-fourth 
cases. There are some studies which suggest that the production of AFP depends on the size 
or  the  degree  of  differentiation  of  the  hepatoma  cells.cxxiii AFP  values  were  high  among 
histopathologically proven HCCs compared to negative HCCs, and it is statistically significant. 
(p<0.02). AFP showed no association with size of the tumor (p>0.05). AFP values were high 
among  HbsAg  positive  HCCs  (p<0.05),  whereas  no  difference  among  anti  HCV  tested 
patients.  When compared according to either CLIP score or Okuda staging there was no 
difference in the serum AFP level to differentiate between early and advanced lesion.
Like  previous  studies  most  of  the  lesions  on  US  were  hypo  echoic  (39.2%)  or 
hyperechoic  (42.7%) in  appearance.  However,  vascular  invasion  observed in  one fifth  of 
cases  (20.8%),  one-third  (34.7%)  having  bilobar  distribution  and  6.9%  had  distant 
metastases. Even when lesions were single they were large enough in most of the cases to 
rule out curative resection. Another study from a tertiary care center in India showed that 56% 
of patients with HCC had tumor size larger than 5cm and high incidence of vascular invasion 
(main portal vein in 43% and right portal vein in 30%) with very low resection rate.34 Right lobe 
of the liver (48.6%) was involved in majority as has been reported in other studies. More than 
half (56.9%) of the patients had a single tumor. Tumor was >5 cm in the majority (62.5%) of 
the patients. Moreover portal vein was thrombosed in 15 (20.8%) patients.
Cytohistopathological  examinations,  including  fine  needle  aspirations  and  biopsies 
were undertaken in 36 patients without complication. Both FNA and biopsy was done for the 
diagnosis  of  HCC  once  a  lesion  was  suspected  on  radiological  investigation.  The 
cytohistological examination was positive in 86.1% of patients and was falsely negative in 
only 6.4% cases.  A similar  observation noted by Kumar et  al.35 It  was safe and easy to 
perform. The larger and advanced lesions might have contributed to better results with FNA in 
the present study. FNA appears to be the best diagnostic modality as it has low false negative 
rate as compared to serum AFP, once a lesion is detectable on CT scan or US. In a country 
like ours, a costly investigation like serum AFP with such low sensitivity should be used if 
cytohistological  examination  is  equivocal  in  patients  with  radiological  suspicion  of  HCC.35 
However,  in  an  otherwise  unapparent  HCC  on  radiological  investigation,  screening  with 
serum  AFP  is  the  only  practical  modality  available  now,  despite  its  limitations.35 
Cytohistological  diagnosis  is  recommended  only  if  atypical  vascular  pattern  observed 
radiological observed in cirrhotic patients. 29 
Almost two-third of patients with HCC had CLIP score of more than 2 and Okuda stage 
2 and 3. The Okuda staging and CLIP score of  HCC revealed a very high proportion of 
advanced lesions in this study with expected low survival.  We could follow up only 8 of our 
patients, with survival varying from 5 months to 24 months. In view of these findings, we need 
to evolve a better screening and surveillance program for early detection of HCC in patients 
with chronic liver disease in our country. 
Summary and Conclusion
1. The study includes total of seventy two patients, mean age was 54 years with male 
female ratio of 3:1.
2. Nearly half of the patients belong to the age group of 60 to 70 years. 
3. Mean preadmission duration of illness was 54 days. 
4. Twenty  two  percent  of  patients  had  cirrhosis  and  asymptomatic  hepatocellular 
carcinoma (HCC) observed only in 2 cases. 
5. Among the symptoms abdominal pain (66.7%) and weight loss (66.7%) were most 
commonly observed symptoms. 
6. Hepatic decompensation was seen in half the patients at first presentation with ascites 
in 56.9%, jaundice in 22.2% and hepatic encephalopathy in 4.2% of patients. 
7. Abdominal lump as a presentation observed in 12.5% of patients. 
8. Hemorrhagic ascites noted in 11.1% of our cases
9. The median serum AFP value of 515 ng/ml (range 1.3–92625) observed in the study 
population. Diagnostic value of AFP >400 ng/ml was present in only 61.5% cases with 
normal AFP in 14 of 70 (18.5%) patients. 
10.More than three fourth of cases had esophageal varies with gastric varices of 8.3%. 
11. HBV was the most common viral etiologic agent associated with HCC, observed in 23 
of 52 (31.9%). Alcohol or HCV alone as an etiological agent was observed in 20.8% 
and 9.7% of cases respectively 
12. The average size of HCC was 6±4 cm (mean±SD). Very large tumors (>5 cm) were 
seen in two-third of cases. 
13.CT appearance of HCC was hypo dense in 21.4%, mixed or heterogeneous density in 
52.4% and hyper dense in 26.2% patients. 
14.Vascular invasion of either major branch of splenoportal axis was seen in one fifth of 
the patients. 
15. Diagnosis of HCC was made based on cytohistology in 31/36 (86.1%) patients.
16. More than three-fourth of HCC was in Okuda stage 2 (72.8%). Only five patients had 
Okuda stage 1 lesion. More than ninety percent of patient had CLIP score of ≥2. The 
serum AFP level was not associated with different stages of Okuda and CLIP Score (P 
>0.05, NS).
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